Mirabegron Completed Phase 3 Trials for Urinary Bladder Diseases\Urologic Diseases / Urinary Bladder, Overactive / Urgency Incontinence Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00662909A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00688688Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00689104Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00912964A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00966004A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder
NCT01043666A Study of YM178 in Subjects With Symptoms of Overactive Bladder
NCT00840645A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients
NCT01972841This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
NCT02045862A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder